RECRUITINGPhase 4INTERVENTIONAL

The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)

The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark: an Open-Label, Pragmatic, Randomised Controlled Trial

About This Trial

The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Consenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 MIE four times daily.

Who May Be Eligible (Plain English)

Who May Qualify: Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnoea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Who Should NOT Join This Trial: 1. Need for immediate hospitalisation at the time of diagnosis. 2. Known allergy to beta-lactam antibiotics. 3. Any coinfection necessitating antibiotic treatment. 4. Use of systemic antibiotics or antivirals within the last month. 5. Pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer). 6. Known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder). 7. Pregnant or lactating. 8. Patients not capable of consenting and/or patients deemed non-suitable for participation by the healthcare professional. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnoea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Exclusion Criteria: 1. Need for immediate hospitalisation at the time of diagnosis. 2. Known allergy to beta-lactam antibiotics. 3. Any coinfection necessitating antibiotic treatment. 4. Use of systemic antibiotics or antivirals within the last month. 5. Pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer). 6. Known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder). 7. Pregnant or lactating. 8. Patients not capable of consenting and/or patients deemed non-suitable for participation by the healthcare professional.

Treatments Being Tested

DRUG

Phenoxymethylpenicillin 1.2 MIE 4 times daily

The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.

Locations (1)

The Research Unit for General Practice Aalborg

Gistrup, Denmark